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Novelty and Impact: 
This study is the first to investigate  a potential association between cancer patients’ usual consultation 
frequency in general practice and the prognosis of cancer. Patients who usually consult their GP rarely are 
more likely to be diagnosed with advanced cancer and to die within the first year after the cancer diagnosis. 
Part of the deficit in cancer survival in Denmark may be attributable to subgroups in the population who 
tend to consult general practice rarely.  
Abbreviations used in manuscript: 
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Abstract 
Cancer survival rates are lower in Denmark than in comparable European countries. This may partly be 
attributable to subgroups of cancer patients who seek medical attention at late disease stages. It is 
unknown if differences in usual (i.e. customary) consultation frequency in general practice are associated 
with cancer prognosis.  
We aimed to estimate the cancer prognosis of cancer patients stratified by their usual consultation 
frequency in general practice.  
We performed a population-based cohort study including 123,943 incident cancer patients aged 50-89 
years diagnosed in Denmark in 2009-2013. We estimated associations between the patient’s usual general 
practitioner (GP) consultation frequency 19-36 months before the cancer diagnosis and all-cause mortality 
by using hazard ratios (HR), estimated by Cox proportional hazards regression. We also estimated the 
associations between the patient’s usual GP consultation frequency and tumour stage, by using logistic 
regression estimates of odds ratios (ORs).  
Patients who usually did not see their GP (non-consulters) had higher all-cause mortality (HR=1.39 (95% CI: 
1.33-1.44)) compared to patients who usually saw their GP three to five times during an 18 months period 
(average consulters). Non-consulters had higher odds of having distant tumour stage (OR=1.46 (95% CI: 
1.38-1.57)) than average consulters. Similar, yet less strong, patterns were seen among patients with low 
usual GP consultation frequency, yet not statistically significant for all cancer types.  
In conclusion, the association between usual GP non-consultation and cancer prognosis is a combination of 
at least two things: a mechanism through more advanced tumour stage and other independent factors.  
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Introduction 
The prognosis of cancer patients has been shown to vary internationally.(1-3) Poorer short-term cancer 
survival is  seen in Denmark and England compared with Finland, Norway, and Sweden.(4) Several studies 
indicate that Danish cancer patients tend to be diagnosed and treated at more advanced disease stages 
than cancer patients in Norway and Sweden.(5-9) The underlying mechanism is unknown, but a 
contributory factor could be that some patients delay seeking medical care. As tumours generally grow 
exponentially, early diagnosis (i.e. early in the tumour’s lifespan) is a crucial factor. (10) After decades of 
conflicting results on the prognostic impact of the time to diagnosis, (11-16) recent evidence suggests that 
increasing mortality is seen with longer time to diagnosis. (17-20) Therefore, it is vital that patients 
promptly seek medical advice when symptoms of potential disease are experienced.(11) 
The poor cancer survival in Denmark and England have been suggested to be partly attributable to a sub-
group of patients who do not seek medical advice until they have developed advanced and fatal cancer.(1)  
Patients with undiagnosed cancer tend to increasingly consult their general practitioner (GP) several 
months before the cancer diagnosis.(21-24) Their consultation pattern thus seems to be influenced by 
symptoms related to the cancer disease.  
Danish residents can consult their GP in several ways: by face-to-face consultation, phone, or email. Danes 
consult their GP 5-7 times on average per year, but eight percent of Danish residents aged 60 years or older 
have not consulted their GP at all during the most recent 12 months.(25) Danish GPs are gatekeepers to the 
rest of the healthcare system and serve as the first point of contact  for medical advice. This organisation 
offers a unique possibility to investigate if differences in the usual GP consultation frequency  are 
associated with the prognosis after diagnosis of cancer.  
The aims of this study were to quantify the size of different sub-groups of Danish cancer patients on the 
basis of their usual consultation pattern in  general practice and to estimate their prognosis and distribution 
of cancer stage. 
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Material and methods 
We performed a population-based cohort study of incident cancer patients who were diagnosed in 2009-
2013 in Denmark.  
Setting  
The 5.6 million residents in Denmark have free access to medical care in the tax-funded healthcare system. 
Around 98% of the Danish population are listed with a general practice, which they can consult for primary 
medical care. The GP is the gatekeeper to secondary healthcare, except for emergencies, ear-nose-throat 
specialists, and eye specialists, who can be accessed directly.(26) 
Study population 
The cancer cohort was identified in the Danish Cancer Registry (DCR), which holds information on the date 
of diagnosis and the tumour characteristics of all cancers diagnosed in Denmark.(27) We identified all first-
time cancer patients aged 50-90 years who were diagnosed from 1 January 2009 to 31 December 2013. 
Patients were eligible if they had no previous cancer diagnosis (apart from non-melanoma skin cancer), had 
a valid civil registration number (i.e. not foreigners treated in Denmark), had been living in Denmark during 
the 36 months preceding diagnosis, and were listed with a Danish general practice.  
The general practice affiliation for each participant was retrieved from the Patient List Register, which is an 
administrative database that contains information on which general practice each citizen is registered with 
at any given time. 
Outcomes 
The primary outcome was all-cause mortality based on the survival time of each patient from the date of 
diagnosis. Information on death and emigration was obtained up to 31 December 2014 from the Danish 
Civil Registration System.(28) The date of diagnosis was obtained from the DCR and corresponds to the 
date of first contact (admission date) with the hospital department at which the cancer diagnosis was first 
registered. If the patient was diagnosed by a private practicing specialist, the date of diagnosis was defined 
as the date of the clinical diagnosis.(29) 
The secondary outcome was tumour stage. Data was obtained from the DCR and was based on the TNM 
staging system. We categorised tumour stage for colorectal, lung, breast, prostate, malignant melanoma, 
and bladder cancers using established cancer-specific algorithms to categorise tumours as either: local, 
regional, distant, or unknown.(30-35) TNM staging information for the remaining cancers was categorised 
using the following principle: local (no positive lymph nodes or metastasis), regional (positive lymph nodes), 
distant (metastatic cancer), and unknown. 
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Exposure 
The primary exposure in the study was the patient’s usual (i.e. customary) consultation pattern in general 
practice. This was defined as the number of daytime face-to-face consultations with a GP, including home 
visits, in the period 19-36 months prior to the date of cancer diagnosis. Data on consultations with general 
practice was extracted from the Danish National Health Service Register, which holds information on all 
contacts and services provided by general practice for remuneration purposes.  
To categorise the usual consultation frequency in general practice accurately, we compared the 
consultation pattern among the cancer patients with a 1:10 sex- and age-matched comparison cohort. The 
comparison cohort was identified in the Danish Civil Registration System, which holds information on all 
citizens in Denmark, including their personal registration number (PRN).(28) Based on this, we categorised 
the cancer patients’ usual consultation frequency into seven categories according to the number of face-to-
face consultations during the 19-36 months prior to the date of their cancer diagnosis. 
Covariates 
We collected demographic and socioeconomic information from Statistics Denmark. Marital status was 
categorised into “married” (married or registered partnership), “widowed and divorced” (widowers, 
divorcees and annulled partnerships), or “single” (never married or registered partnership). Data on taxable 
income was extracted for the calendar year preceding the index date to eliminate the risk of influence from 
the cancer diagnosis on income. Income was categorised into tertiles of the OECD-modified scale. The 
highest attained level of education was categorised according to the International Standard Classification of 
Education(36) into “basic” (ISCED levels 1-2), “short” (ISCED levels 3-4), and “long”(ISCED levels 5-6). 
Patients with missing information on educational level were assigned “basic” educational level as these are 
most often uneducated.(37) The Charlson Comorbidity Index (CCI) was used to account for comorbidity.(38) 
A CCI score was calculated on the basis of diagnoses registered in the Danish National Patient Register in 
the 10-year-period preceding the 18 months prior to the patient’s cancer diagnosis. We computed the total 
CCI score for each patient and grouped levels of comorbidity into “none” (CCI score = 0), “moderate” (CCI 
score = 1–2), and “high” (CCI score ≥ 3). 
Statistical analyses 
Analyses were stratified on four major types of cancer according to the International Classification of 
Diseases, 10th revision (ICD-10): colorectal (C18-C20), lung (C34), female breast (C50), prostate cancer 
(C61), and a fifth category containing all other cancer types. The analyses were performed for each sex 
separately as gender differences are known to exist in the use of general practice.  
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The consultation pattern between the cancer cohort and the comparison subjects was compared by 
calculating monthly (mean) rates and rate ratios with corresponding 95% confidence intervals (95% CIs) 
using a negative binominal regression model with robust variance estimation.  
We used Cox proportional hazards regression to quantify the relative hazard of death from any cause in 
relation to the patients’ usual consultation frequency. All analyses were adjusted for age (linear and second 
order terms), sex (binary), marital status (categorical), educational level (categorical), income (categorical), 
and CCI score (categorical) of the individual patient. In the analysis of all cancers combined, we also 
adjusted for main type of cancer (colorectal, lung, female breast, prostate, and other cancer) as a 
categorical variable. The analyses focused on the one-year follow-up time after the cancer diagnosis. 
Patients surviving beyond one-year follow-up were censored at the one-year time point.  
We used logistic regression to analyse the association between the patient’s usual consultation pattern and 
the tumour stage. Analyses were adjusted for the same covariates as outlined above. Missing data on 
tumour stage is a well-known concern in the DCR and is dependent on sex, age, cancer type, and CCI score. 
(30-35;39) We examined the distribution of missing tumour stage by all variables used in the model to 
investigate if multiple imputation was feasible. Multiple imputation of missing values for tumour stage was 
conducted by using a multivariate model with one-year vital status, sex, age, marital status, educational 
level, income, CCI, and cancer type as predictive values. We imputed twenty datasets in a chained 
sequence and used Rubin’s formula to combine the outcomes from the imputed datasets.  
Data was analysed using the statistical software Stata 14.0 (StataCorp LP, TX).  
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Results 
We identified 123,943 eligible incident cancer cases and 1,239,424 age- and sex-matched comparison 
subjects. The cancer cases had slightly higher comorbidity scores than the comparison subjects, mainly for 
lung cancer (Table A1, Appendix). The cancer cases consisted of 17,138 (13.8%) colorectal cancers, 17,861 
(14.4%) lung cancers, 18,396 (14.8%) breast cancers, 19,348 (15.6%) prostate cancers, and 51,200 (41.3%) 
other cancer types (Table 1).  
Usual use of general practice  
A stable usual use of general practice was seen for both cancer patients and comparison subjects in the 19-
36 months prior to diagnosis, although fewer cancer patients had a low  GP use compared to the 
comparison subjects (9.3% and 10.2%, respectively) (Table A1, Appendix). During this period, 9% of cancer 
patients (8% women, 11% men) did not have any face-to-face contact with their GP (non-consulters), and 
23% of cancer cases consulted their GP 3-5 times (average consulters)(Table 1).  
Mortality according to usual GP consultation frequency 
At one-year follow-up, 33,761 (27%) of the cancer patients had died (26% of women, 29% of men). The 
proportion of patients who died during the first year varied according to sex and type of cancer, ranging 
from 4% for female breast cancer patients to 64% for male lung cancer patients (Table 1). 
The proportion of deaths was 30% among the patients who had not consulted their GP; 24% among the 
patients who had consulted their GP two to five times, and 34% among the patients who had consulted 
their GP more than 15 times (Table 2). The pattern of deaths according to usual GP consultation frequency 
was similar for both women and men separately, but higher death rates were found for men in all groups 
(data not shown). 
Unadjusted mortality was associated with usual GP consultation frequency, resulting in a concave curve, 
with the pole around 3-9 consultations with a GP. After adjustment, the association changed to a “hockey 
stick” curve (Figure 1) with a hazard ratio (HR) of 1.39 (95%CI: 1.33-1.44) in the group of non-consulters 
compared to average consulters (three to five consultations) during the period 19-36 months before their 
cancer diagnosis (Table 2). Patients with one or two GP consultations during the same period had 
intermediate HRs of 1.15 (95%CI: 1.10-1.20) and 1.06 (95%CI: 1.01-1.11), respectively (Table 2). 
For specific cancers, the hazard ratios among non-consulters ranged from 2.54 (95%CI: 1.99-3.24) among 
breast cancer patients to 1.30 (95%CI: 1.23-1.38) among patients with other cancer types. All cancer types 
investigated had the same overall pattern although with varying HRs, ranging from 1.07 (95%CI: 0.93-1.22) 
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for colorectal cancer patients to 1.41 (95%CI: 1.08-1.83) for prostate cancer patients (Table 2). The patterns 
were similar for males and females. 
Tumour stage according to usual GP consultation frequency 
Twenty percent of the patients were diagnosed with distant cancer, ranging from 4% for breast cancer 
patients to 58% for male lung cancer patients. Missing data on tumour stage was encountered for 26% of 
patients, with variations across cancer types (Table 1,  Table A2, Appendix). The proportion of distant 
cancers diagnosed among patients with non-missing tumour stage was 25% for non-consulters and 20% in 
the remaining patients (data not shown). The pattern of distant tumour stage according to usual GP 
consultation frequency was similar for both women and men, but with slightly higher proportion of distant 
cancers for men than women (data not shown). 
Low usual GP consultation frequency was associated with distant tumour stage (Table 3). The odds of 
having distant tumour stage was 1.46 (95%CI: 1.38-1.57) times higher in non-consulters than in average 
consulters. Patients with one or two GP consultations during the same period had ORs of 1.14 (95%CI: 1.07-
1.22) and 1.11 (95%CI: 1.05-1.18), respectively. 
For specific cancers, the ORs of having distant tumour stage among non-consulters varied from 3.52 
(95%CI: 2.74-4.53) among breast cancer patients to 1.28 (95%CI: 1.17-1.40) among patients with other 
cancer types than colorectal, lung, breast, or prostate cancer. The same pattern was observed for all cancer 
types investigated with ORs ranging from 1.06 (95%CI: 0.92-1.22) for colorectal cancer patients to 1.53 
(95%CI: 1.22-1.88) for prostate cancer patients (Table 3).  
Mortality according to usual GP consultation frequency conditioned on tumour stage  
After adjustment for tumour stage at diagnosis, the association between usual GP consultation frequency 
and mortality attenuated. However, the same pattern was observed as in the fully adjusted model without 
tumour stage (Table A3, Appendix), with a HR of 1.28 (95%CI: 1.23-1.34) among non-consulters compared 
to average consulters. For specific cancers, the hazard ratios among non-consulters ranged from 1.60 
(95%CI: 1.25-2.04) among breast cancer patients to 1.23 (95%CI: 1.09-1.38) among colorectal cancer 
patients. The same pattern was observed for all cancer types investigated although with varying HRs (Table 
A2, Appendix).  
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Discussion 
Principal findings 
This analysis of mortality and tumour stage among more than 120,000 cancer patients in Denmark shows 
that low usual consultation frequency in general practice is associated with a higher risk of being diagnosed 
with distant tumour stage and a higher risk of dying in the first year after a cancer diagnosis. The 
association was strongest for patients who did not consult their GP during the 19-36 months before their 
diagnosis. Adjusting for age, comorbidity, and socioeconomic position explained the poorer prognosis 
among patients with high consultation frequency  in general practice, but it did not explain the poor 
prognosis among patients with low usual GP consultation frequency. This indicates that the findings may be 
explained by differences in healthcare-seeking behaviour. 
Strengths and limitations 
The strengths of this study include the population-based design, which was permitted by the uniformly 
organised healthcare system in Denmark, the identification of cancer cases in the DCR, and the complete 
follow-up through national population-based registries. This reduced the risk of selection and information 
bias. Furthermore, the large study population provided high statistical precision. 
Another major strength was the stable and comparable consultation rates in general practice between the 
cancer patients and the  sex- and age-matched comparison subjects. The risk of misclassifications 
concerning the  usual GP consultation frequency among the patients use was thereby minimised. 
Additionally, the grouping of cancer patients by number of contacts reflects the true usual GP consultation 
pattern. 
A potential limitation was that we included only face-to-face contacts. Some patients may prefer telephone 
consultations, and we have underestimated the total number of contacts between the patients and the GP. 
However, from a clinical perspective, the number of face-to-face contacts during more than 1.5 years 
before the cancer diagnosis is a strong indicator of the usual healthcare-seeking behaviour, even without 
considering other types of contacts that are more trivial.  
The study was based on national population-based registries, and we were not able to adjust for potential 
confounders such as smoking, alcohol consumption, and physical fitness. As these factors are strongly 
associated with income and educational level, (40;41) a part of their potential confounding effect has 
already been accounted for. Thus, we believe that the possible effect of e.g. alcohol consumption or 
smoking cannot fully explain the observed associations. 
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Despite its high specificity, the Charlson Comorbidity Index (CCI) does not measure comorbidity as precise 
as clinical data.(42) Furthermore, the CCI score requires that the patient has actually been in contact with a 
hospital. Consequently, the CCI score might be too low in the patient groups with low levels of GP 
consultations. Nevertheless, we observed almost no changes in the estimates for the outcomes of interest 
when we adjusted for comorbidity, which indicates that the impact is negligible.   
Tumour stage is likely to be misclassified due to missing data on tumour stage in the DCR. (39)  We used 
well-established algorithms to produce comparable tumour stage information. (30-35) Our complete case 
analysis and the analysis using multiple imputation of missing data on tumour stage gave identical results, 
which makes potential bias due to missing data on tumour stage unlikely.  
Misclassification of tumour stage in the DCR cannot be ruled out. (27) Thus, residual confounding from 
tumour stage will be at play in the sub-analysis of mortality according to usual GP consultation frequency 
when adjusted for tumour stage. Therefore, these results should be interpreted with caution. 
Comparison with relevant literature and interpretation 
Direct comparison with other studies of the association between consultation frequency in general practice  
and mortality is not possible due to the absence of similar studies. Nevertheless, studies measuring 
continuity of care have reported an association between higher continuity of care in primary care and 
lower mortality.(43-45) In line with our findings, Wolinsky et al have reported that patients consulting 
primary care have lower likelihood of early death than non-consulting patients .(45) Similarly, cancer 
patients diagnosed with colorectal cancer through an “emergency route” who has a poorer prognosis are 
less likely to consult their GP  in the 24-36 months prior to their diagnosis.(46;47)  
Lack of evidence is also seen on the association between usual healthcare-seeking and tumour stage. A 
French study on head and neck cancers found that patients consulting their GP during the last year before a 
cancer diagnosis had a lower risk of being diagnosed with a tumour at an advanced stage and that this 
association had a dose-response effect.(48) Although the reported association is based on the time period 
immediately before a cancer diagnosis,(48) it still indicates that consulting a GP increases the chance of 
early detection of cancer.  
Patients with low GP consultation frequency are known to have a higher mortality.(43-45) Our findings 
added new knowledge on the association between usual GP consultation frequency and advanced cancer 
stage at diagnosis. As the observed association between usual GP consultation frequency and mortality 
attenuated, but this association remained when we adjusted for tumour stage in the analyses; this  clearly 
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indicates that there is a  connection between late-stage diagnosis and increased mortality. Yet, other 
independent factors, such as a patient’s health-care seeking behaviour, seem to play a role.  
The patients who did not consult their GP during the 19-36 months before the diagnosis (non-consulters) 
had a cumulative survival that was 6.1 percentage point lower than the group of patients who consulted 
the GP three to five times (average consulters) (75.6% vs. 81.7%). This difference applies to 11,567 patients 
who usually never consulted their GP, which suggests that 706 (20.4%) of the patients who very rarely 
consulted their GP died prematurely compared to the patients who consulted their GP three to five times. 
These 706 deaths correspond to 140 deaths annually. This number is not a trivial figure in the Danish 
setting; it is slightly more than the 120 annual deaths caused by cervical cancer each year in Denmark.(49) 
Furthermore, the 700 premature deaths account for 2.1% of the observed 33,760 deaths in the present 
study; this indicates that 2% of all deaths within one year among incident cancer patients in Denmark may 
be related to low usual consultation frequency in general practice. 
The data from this study did not allow us to investigate why these patients had low healthcare seeking. It 
may be explained by other diseases, e.g. mental illness, which should be elucidated in future research.  
Conclusion 
In this study, we found an association between low usual consultation frequency in general practice among 
cancer patients and both higher risk of being diagnosed with distant tumour stage and increased short-
term mortality. The association between GP consultation frequency and mortality is a combination of at 
least two things: a mechanism through more advanced tumour stage and other independent factors. 
Patients who usually consult their GP rarely may also have delayed help-seeking for cancer symptoms or 
lower access to healthcare than patients who see their GP on a more regular basis. To develop future 
interventions that may improve the prognosis for patients with low usual consultation frequency  in general 
practice, the characteristics of these patients should be described and the processes behind their 
consultation pattern  should be explored. 
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 Figure 1: Hazard ratios of dying during the first year after diagnosis according to the number of consultations at a general practice 19-36 
months before diagnosis of four cancer types, other types of cancer, and in total. Estimates are adjusted for age, sex, education, income, 
marital status, and comorbidity.  
 Table 1: Patient characteristics by cancer site and total (n=123,943). 
  Colorectal   Lung   Breast   Prostate   Other   Total 
  Women Men  Women Men  Women  Men  Women Men  Women Men Total 
    n (%) n (%)   n (%) n (%)   n (%)   n (%)   n (%) n (%)   n (%) n (%) n (%) 
Total 
  7,853 (45.8) 9,285 (54.2)  8,618 (48.3) 9,243 (51.7)  18,396 (100)  19,348 (100)  23,960 (46.8) 27,240 (53.2)  58,827 (47.5) 65,116 (52.5) 123,943 (100) 
Died at one-year follow up 1,855 (23.6) 2,068 (22.3)  4,996 (58.0) 5,920 (64.0)  800 (4.3)  1,036 (5.4)  7,458 (31.1) 9,628 (35.3)  15,109 (25.7) 18,652 (28.6) 33,761 (27.2) 
Face-to-face contacts                             
None  672 (8.6) 1,113 (12.0)  633 (7.3) 979 (10.6)  1,512 (8.2)  1,748 (9.0)  1,869 (7.8) 3,041 (11.2)  4,686 (8.0) 6,881 (10.6) 11,567 (9.3) 
1  570 (7.3) 794 (8.6)  560 (6.5) 765 (8.3)  1,496 (8.1)  1,645 (8.5)  1,680 (7.0) 2,371 (8.7)  4,306 (7.3) 5,575 (8.6) 9,881 (8.0) 
2  611 (7.8) 795 (8.6)  600 (7.0) 696 (7.5)  1,607 (8.7)  1,679 (8.7)  1,786 (7.5) 2,359 (8.7)  4,604 (7.8) 5,529 (8.5) 10,133 (8.2) 
3-5  1,791 (22.8) 2,182 (23.5)  1,793 (20.8) 2,040 (22.1)  4,435 (24.1)  4,789 (24.8)  5,350 (22.3) 6,206 (22.8)  13,369 (22.7) 15,217 (23.4) 28,586 (23.1) 
6-9  1,829 (23.3) 1,954 (21.0)  2,042 (23.7) 1,971 (21.3)  4,210 (22.9)  4,356 (22.5)  5,538 (23.1) 5,618 (20.6)  13,619 (23.2) 13,899 (21.3) 27,518 (22.2) 
10-15  1,330 (16.9) 1,321 (14.2)  1,641 (19.0) 1,522 (16.5)  3,082 (16.8)  3,069 (15.9)  4,345 (18.1) 4,279 (15.7)  10,398 (17.7) 10,191 (15.7) 20,589 (16.6) 
≥ 16 1,050 (13.4) 1,126 (12.1)  1,349 (15.7) 1,270 (13.7)  2,054 (11.2)  2,062 (10.7)  3,392 (14.2) 3,366 (12.4)  7,845 (13.3) 7,824 (12.0) 15,669 (12.6) 
Tumour stage                             
Local  2,542 (32.4) 3,002 (32.3)  1,703 (19.8) 1,561 (16.9)  10,088 (54.8)  11,154 (57.6)  9,187 (38.3) 9,016 (33.1)  23,520 (40.0) 24,733 (38.0) 48,253 (38.9) 
Regional  1,777 (22.6) 2,196 (23.7)  1,591 (18.5) 1,901 (20.6)  5,610 (30.5)  446 (2.3)  1,968 (8.2) 3,066 (11.3)  10,946 (18.6) 7,609 (11.7) 18,555 (15.0) 
Distant  1,847 (23.5) 2,185 (23.5)  4,882 (56.6) 5,338 (57.8)  742 (4.0)  1,856 (9.6)  4,058 (16.9) 4,432 (16.3)  11,529 (19.6) 13,811 (21.2) 25,340 (20.4) 
Unknown  1,687 (21.5) 1,902 (20.5)  442 (5.1) 443 (4.8)  1,956 (10.6)  5,892 (30.5)  8,747 (36.5) 10,726 (39.4)  12,832 (21.8) 18,963 (29.1) 31,795 (25.7) 
Age group (years)                             
50-59  983 (12.5) 1,219 (13.1)  1,434 (16.6) 1,234 (13.4)  5,346 (29.1)  1,982 (10.2)  4,707 (19.6) 5,455 (20.0)  12,470 (21.2) 9,890 (15.2) 22,360 (18.0) 
60-69  2,194 (27.9) 3,171 (34.2)  2,926 (34.0) 3,194 (34.6)  7,536 (41.0)  8,099 (41.9)  7,691 (32.1) 10,017 (36.8)  20,347 (34.6) 24,481 (37.6) 44,828 (36.2) 
70-79  2,636 (33.6) 3,199 (34.5)  2,925 (33.9) 3,346 (36.2)  3,443 (18.7)  6,829 (35.3)  6,971 (29.1) 7,942 (29.2)  15,975 (27.2) 21,316 (32.7) 37,291 (30.1) 
80-89  2,040 (26.0) 1,696 (18.3)  1,333 (15.5) 1,469 (15.9)  2,071 (11.3)  2,438 (12.6)  4,591 (19.2) 3,826 (14.0)  10,035 (17.1) 9,429 (14.5) 19,464 (15.7) 
Comorbidity                             
None  6,039 (76.9) 6,657 (71.7)  5,661 (65.7) 5,710 (61.8)  14,923 (81.1)  14,737 (76.2)  18,178 (75.9) 19,186 (70.4)  44,801 (76.2) 46,290 (71,1) 91,091 (73.5) 
Moderate 1,527 (19,4) 2,123 (22.9)  2,534 (29.4) 2,806 (30.4)  2,992 (16.3)  3,885 (20.1)  4,825 (20.1) 6,277 (23.0)  11,878 (20.2) 15,091 (23.2) 26,969 (21.8) 
High  287 (3.7) 505 (5.4)  423 (4.9) 1,150 (12.4)  481 (2.6)  726 (3.8)  957 (4.0) 1,777 (6.5)  2,148 (3.7) 4,158 (6.4) 6,306 (5.1) 
Educational level                             
Basic  4,119 (52.5) 3,435 (37.0)  5,144 (59.7) 4,125 (44.6)  7,379 (40.1)  6,287 (32.5)  11,853 (49.5) 10,059 (36.9)  28,495 (48.4) 23,906 (36,7) 52,401 (42.3) 
Short 2,545 (32.4) 4,001 (43.1)  2,527 (29.3) 3,941 (42,6)  6,658 (36.2)  8,305 (42.9)  7,674 (32.0) 11,969 (43.9)  19,404 (33.0) 28,216 (43.3) 47,620 (38.4) 
Long  1,189 (15.1) 1,849 (19.9)  947 (11.0) 1,177 (12.7)  4,359 (23.7)  4,756 (24.6)  4,433 (18.5) 5,212 (19.1)  10,928 (18.6) 12,994 (20.0) 23,922 (19.3) 
Disposable income                              
Low  3,315 (42.2) 3,037 (32.7)  3,767 (43.7) 3,725 (40.3)  6,152 (33.4)  5,466 (28.3)  9,555 (39.9) 8,437 (31.0)  22,789 (38.7) 20,665 (31,7) 43,454 (35.1) 
Intermediate 2,924 (37.2) 2,936 (31.6)  3,447 (40.0) 3,315 (35.9)  6,331 (34.4)  5,606 (29.0)  8,672 (36.2) 8,869 (32.6)  21,374 (36.3) 20,726 (31.8) 42,100 (34.0) 
High  1,614 (20.6) 3,312 (35.7)  1,404 (16.3) 2,203 (23.8)  5,912 (32.1)  8,276 (42.8)  5,733 (23.9) 9,934 (36.5)  14,663 (24.9) 23,725 (36.4) 38,388 (31.0) 
Marital status                             
Married/partner 3,847 (49.0) 6,467 (69.6)  3,888 (45.1) 5,763 (62.3)  10,805 (58.7)  14,399 (74.4)  12,417 (51.8) 18,067 (66.3)  30,957 (52.6) 44,696 (68.6) 75,653 (61.0) 
Divorced/widowed 3,539 (45.1) 2,047 (22.0)  4,229 (49.1) 2,638 (28.5)  6,229 (33.9)  3,712 (19.2)  9,888 (41.3) 6,329 (23.2)  23,885 (40.6) 14,726 (22.6) 38,611 (31.2) 
Single/never married 467 (5.9) 771 (8.3)   501 (5.8) 842 (9.1)   1,360 (7.4)   1,237 (6.4)   1,655 (6.9) 2,844 (10.4)   3,983 (6.8) 5,694 (8.7) 9,677 (7.8) 
 
 Table 2: Hazard ratios (HRs) for death one year after diagnosis according to number of face-to-face contacts with a 
GP 19-36 months prior to patient’s primary cancer diagnosis.  
Face-to-face contacts  
Cancer  
patients 
Deaths at 1- 
year follow-up 
HRs and 95% CIs adjusted for age, sex, education, income, 
marital status, and comorbidity1 
All Female Male  
N n (%) HR (95%CI) HR (95%CI) HR (95%CI) 
Colorectal (n=17,138)          
None 1,785 436 (24.4) 1.33 (1.19;1.50) 1.41 (1.18;1.68) 1.28 (1.10;1.50) 
1 1,364 286 (21.0) 1.07 (0.93;1.22) 1.03 (0.84;1.26) 1.11 (0.92;1.32) 
2 1,406 263 (18.7) 0.89 (0.78;1.02) 1.01 (0.83;1.22) 0.80 (0.66;0.97) 
3-5 3,973 859 (21.6) 1.00 
 
1.00 
 
1.00 
 
6-9 3,783 809 (21.4) 0.89 (0.81;0.97) 0.85 (0.74;0.98) 0.90 (0.79;1.03) 
10-15 2,651 647 (24.4) 0.90 (0.85;1.00) 0.89 (0.77;1.03) 0.92 (0.80;1.06) 
≥ 16 2,176 623 (28.6) 0.94 (0.85;1.05) 0.97 (0.83;1.13) 0.93 (0.80;1.07) 
Lung (n=17,861)          
None 1,612 1,105 (68.5) 1.45 (1.35;1.56) 1.38 (1.22;1.54) 1.50 (1.40;1.68) 
1 1,325 828 (62.5) 1.20 (1.11;1.30) 1.18 (1.05;1.34) 1.21 (1.09;1.35) 
2 1,296 793 (61.2) 1.12 (1.04;1.22) 1.10 (0.98;1.24) 1.14 (1.02;1.27) 
3-5 3,833 2,218 (57.9) 1.00  1.00  1.00  
6-9 4,013 2,414 (60.2) 1.02 (0.96;1.08) 0.99 (0.91;1.09) 1.05 (0.96;1.13) 
10-15 3,163 1,906 (60.3) 0.99 (0.93;1.05) 0.96 (0.88;1.05) 1.02 (0.93;1.10) 
≥ 16 2,619 1,652 (63.1) 0.99 (0.93;1.07) 0.93 (0.85;1.02) 1.05 (0.96;1.14) 
Female Breast (n=18,396)          
None 1,512 112 (7.4) 2.54 (1.99;3.24) 2.54 (1.99;3.24)   
1 1,496 58 (3.9) 1.30 (0.96;1.76) 1.30 (0.96;1.76)   
2 1,607 62 (3.9) 1.27 (0.95;1.70) 1.27 (0.95;1.70)   
3-5 4,435 161 (3.6) 1.00  1.00    
6-9 4,210 151 (3.6) 0.81 (0.65;1.02) 0.81 (0.65;1.02)   
10-15 3,082 130 (4.2) 0.83 (0.66;1.04) 0.83 (0.66;1.04)   
≥ 16 2,054 126 (6.1) 0.90 (0.71;1.14) 0.90 (0.71;1.14)   
Prostate (n=19,348)          
None 1,748 96 (5.5) 1.62 (1.27;2.08)   1.62 (1.27;2.08) 
1 1,645 77 (4.7) 1.41 (1.08;1.83)   1.41 (1.08;1.83) 
2 1,679 71 (4.2) 1.13 (0.86;1.48)   1.13 (0.86;1.48) 
3-5 4,789 188 (3.9) 1.00    1.00  
6-9 4,356 219 (5.0) 1.08 (0.89;1.31)   1.08 (0.89;1.31) 
10-15 3,069 190 (6.2) 1.15 (0.94;1.41)   1.15 (0.94;1.41) 
≥ 16 2,062 195 (9.5) 1.44 (1.18;1.76)   1.44 (1.18;1.76) 
Other cancers (n=51,200)          
None 4,910 1,693 (34.5) 1.30 (1.23;1.38) 1.32 (1.20;1.45) 1.27 (1.18;1.37) 
1 4,051 1,245 (30.7) 1.11 (1.04;1.18) 1.16 (1.05;1.28) 1.07 (0.98;1.16) 
2 4,145 1,208 (29.1) 1.06 (0.99;1.13) 1.03 (0.92;1.14) 1.07 (0.99;1.17) 
3-5 11,556 3,510 (30.4) 1.00  1.00  1.00  
6-9 11,156 3,651 (32.7) 0.98 (0.93;1.02) 0.95 (0.89;1.02) 1.00 (0.94;1.07) 
10-15 8,624 3,021 (35.0) 0.98 (0.93;1.02) 0.96 (0.89;1.03) 0.99 (0.93;1.06) 
≥ 16 6,758 2,758 (40.8) 1.04 (0.99;1.10) 1.01 (0.94;1.09) 1.07 (1.00;1.15) 
Total (n=123,943)          
none 11,567 3,442 (29.8) 1.39 (1.33;1.44) 1.41 (1.32;1.50) 1.36 (1.30;1.44) 
1 9,881 2,494 (25.2) 1.15 (1.10;1.20) 1.16 (1.08;1.24) 1.14 (1.07;1.21) 
2 10,133 2,397 (23.7) 1.06 (1.01;1.11) 1.05 (0.98;1.13) 1.06 (1.00;1.13) 
3-5 28,586 6,936 (24.3) 1.00  1.00  1.00  
6-9 27,518 7,244 (26.3) 0.98 (0.95;1.01) 0.94 (0.90;0.99) 1.01 (0.96;1.05) 
10-15 20,589 5,894 (28.6) 0.97 (0.94;1.01) 0.94 (0.89;0.99) 1.00 (0.95;1.05) 
≥ 16 15,669 5,354 (34.2) 1.02 (0.98;1.06) 0.97 (0.92;1.02) 1.06 (1.01;1.12) 
Estimates in bold are statistically significant at p ≤ 0.05 level. 1In the total analyses, the estimates were also adjusted for cancer type. 
 
 
  
Table 3: Odds ratios (ORs) of having distant tumour stage according to number of face-to-face contacts with a GP 19-
36 months prior to patient’s primary cancer diagnosis compared to 3-5 contacts after multiple imputation of missing 
tumour stage; displayed by cancer type and total.  
Face-to-face contacts  Cancer 
patients 
Distant stage ORs of having distant tumour stage adjusted for age, sex, 
education, income, marital status, and comorbidity1   
All Female Male 
N n2 (%)3 OR (95%CI) OR (95%CI) OR (95%CI) 
Colorectal          
None 1,785 678 (38.0) 1.39 (1.22;1.57) 1.41 (1.15;1.74) 1.36 (1.16;1.60) 
1 1,364 434 (31.8) 1.06 (0.92;1.22) 1.14 (0.92;1.43) 1.00 (0.82;1.21) 
2 1,406 483 (34.4) 1.18 (1.03;1.36) 1.34 (1.09;1.65) 1.07 (0.90;1.28) 
3-5 3,973 1,225 (30.8) 1.00  1.00  1.00  
6-9 3,783 1,080 (28.5) 0.88 (0.79;0.98) 0.90 (0.77;1.04) 0.87 (0.75;1.00) 
10-15 2,651 729 (27.5) 0.81 (0.72;0.93) 0.79 (0.66;0.95) 0.84 (0.71;1.00) 
≥ 16 2,176 546 (25.1) 0.70 (0.61;0.80) 0.73 (0.60;0.88) 0.68 (0.57;0.82) 
Lung           
None 1,612 1,097 (68.1) 1.41 (1.24;1.60) 1.47 (1.20;1.79) 1.38 (1.16;1.63) 
1 1,325 831 (62.7) 1.10 (0.97;1.26) 1.17 (0.95;1.43) 1.07 (0.90;1.27) 
2 1,296 838 (64.7) 1.20 (1.05;1.37) 1.37 (1.12;1.67) 1.08 (0.90;1.30) 
3-5 3,833 2,319 (60.5) 1.00  1.00  1.00  
6-9 4,013 2,418 (60.3) 0.98 (0.89;1.08) 0.97 (0.85;1.1) 1.00 (0.88;1.14) 
10-15 3,163 1,828 (57.8) 0.88 (0.80;0.97) 0.88 (0.76;1.01) 0.90 (0.78;1.04) 
≥ 16 2,619 1,486 (56.7) 0.84 (0.75;0.93) 0.86 (0.74;1.00) 0.82 (0.71;0.96) 
Breast          
None 1,512 177 (11.7) 3.52 (2.74;4.53) 3.52 (2.74;4.53)   
1 1,496 72 (4.8) 1.35 (0.99;1.85) 1.35 (0.99;1.85)   
2 1,607 75 (4.7) 1.30 (0.95;1.78) 1.30 (0.95;1.78)   
3-5 4,435 177 (4.0) 1.00  1.00    
6-9 4,210 170 (4.0) 0.91 (0.72;1.15) 0.91 (0.72;1.15)   
10-15 3,082 122 (4.0) 0.79 (0.61;1.04) 0.79 (0.61;1.04)   
≥ 16 2,054 84 (4.1) 0.71 (0.52;0.95) 0.71 (0.52;0.95)   
Prostate          
None 1,748 328 (18.8) 1.82 (1.52;2.18)   1.82 (1.52;2.18) 
1 1,645 267 (16.2) 1.53 (1.24;1.88)   1.53 (1.24;1.88) 
2 1,679 178 (10.6) 0.87 (0.70;1.09)   0.87 (0.70;1.09) 
3-5 4,789 588 (12.3) 1.00    1.00  
6-9 4,356 567 (13.0) 0.95 (0.81;1.10)   0.95 (0.81;1.10) 
10-15 3,069 438 (14.3) 0.96 (0.82;1.14)   0.96 (0.82;1.14) 
≥ 16 2,062 342 (16.6) 0.99 (0.82;1.18)   0.99 (0.82;1.18) 
Other           
None 4,910 1,188 (24.2) 1.28 (1.17;1.40) 1.34 (1.17;1.53) 1.24 (1.10;1.39) 
1 4,051 857 (21.2) 1.09 (0.98;1.20) 1.16 (1.00;1.35) 1.03 (0.90;1.17) 
2 4,145 886 (21.4) 1.10 (1.00;1.21) 1.10 (0.96;1.27) 1.10 (0.97;1.21) 
3-5 11,556 2,368 (20.5) 1.00  1.00  1.00  
6-9 11,156 2,374 (21.3) 1.00 (0.93;1.07) 0.99 (0.89;1.09) 1.01 (0.91;1.11) 
10-15 8,624 1,891 (21.9) 0.99 (0.92;1.07) 1.00 (0.90;1.12) 0.99 (0.89;1.09) 
≥ 16 6,758 1,522 (22.5) 0.97 (0.90;1.06) 0.99 (0.88;1.11) 0.96 (0.86;1.08) 
Total           
None 11,567 3,468 (30.0) 1.46 (1.38;1.54) 1.57 (1.43;1.72) 1.40 (1.30;1.51) 
1 9,881 2,461 (24.9) 1.14 (1.07;1.22) 1.72 (1.06;1.29) 1.12 (1.03;1.23) 
2 10,133 2,460 (24.3) 1.11 (1.05;1.18) 1.21 (1.10;1.32) 1.05 (0.97;1.14) 
3-5 28,586 6,676 (23.4) 1.00  1.00  1.00  
6-9 27,518 6,609 (24.0) 0.96 (0.92;1.01) 0.95 (0.89;1.02) 0.97 (0.91;1.04) 
10-15 20,589 5,008 (24.3) 0.92 (0.88;0.97) 0.91 (0.84;0.97) 0.94 (0.88;1.01) 
≥ 16 15,669 3,980 (25.4) 0.88 (0.83;0.93) 0.87 (0.81;0.94) 0.89 (0.82;0.96) 
Estimates in bold are statistically significant at p≤0.05 level. 1In the total analyses, estimates were also adjusted for cancer type. 2Estimated 
from the proportion derived from multiple imputation. 3Percentage of distant cancers out of number of cases in face-to-face group. 
 
